While many observers following ESMO and WCLC next month will be keen on watching the phase 3 trial readouts, there’s plenty of insights to be gleaned from other research too.

For example, if we want to maintain market share of existing therapies on the market then we may need to devise solid strategies for handling combinations in the face of new competitors.

Ideally, these should be rational based on information around acquired resistance or immune escape.

Increasingly research on biomarkers as well as genomic and even transcriptomic data is becoming more commonplace.

Here we shine a light on a number of key studies, which may help us move forward with future clinical trials…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by